What is the present world scenario of intellectual property rights with respect to life materials? Although India is second in the world to file patents, still only a few have been commercialized. Explain the reasons behind this less commercialization.
Set out the global IPR position on living material clearly, then give the causes behind India's gap between patent filing and commercialisation.
Common trap: Answer both halves. The first needs TRIPS Article 27.3(b), landmark cases and the 2024 WIPO treaty; the second needs causes specific to India's innovation system, not generic statements about red tape.
SyllabusAwareness in the fields of IT, Space, Computers, robotics, nano-technology, bio-technology and issues relating to intellectual property rights.
Model answer
10 marks · 150-word limitSince Diamond v. Chakrabarty (1980), when the US Supreme Court allowed a patent on an engineered bacterium, IP over micro-organisms, genes and plant varieties has widened, while developing countries seek safeguards for biodiversity and traditional knowledge.
- Patents filed for rankings and grants
- Weak industry-academia links
- Few licensing and technology transfer offices
- Scarce risk capital and scale-up funding
- Patent lapses without commercial use
Global scenario on life materials
- TRIPS Article 27.3(b): Members may exclude plants and animals from patents but must patent micro-organisms and protect plant varieties by patents or a sui generis system.
- Judicial limits: In Myriad Genetics (2013) the US Supreme Court held naturally occurring DNA unpatentable, while synthetic cDNA could be patented.
- Access and benefit sharing: The CBD (1992) and Nagoya Protocol (2010) affirm sovereignty over genetic resources; the WIPO treaty of May 2024 requires patent applicants to disclose their origin and associated traditional knowledge.
- India's position: Section 3(j) of the Patents Act, 1970 excludes plants, animals and seeds, Section 3(d) blocks evergreening (Novartis, 2013), and the PPV&FR Act, 2001 protects farmers' rights.
Reasons for low commercialisation
- Filing for metrics: Many academic patents are filed for rankings and promotions, not market need.
- Low R&D spending: Gross expenditure on R&D is below 1% of GDP, with a small private share, so few firms can develop and scale inventions.
- Weak transfer ecosystem: Technology transfer offices and licensing networks are thin, and biotech risk capital is scarce.
- Regulatory and legal hurdles: Long biotech approvals, disputes over trait patents such as Bt cotton, and renewal fees make many patents lapse.
Filings are a strength only if patents become products. Linking academic incentives to licensing, the Anusandhan National Research Foundation, tech-transfer offices and venture funding can turn ideas into marketable innovation while keeping biodiversity safeguards.
Read more — sources
- OfficialWTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Article 27
- OfficialThe Patents Act, 1970 (as amended in 2005) — Section 3
- OfficialWIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge, 2024
- ReportWIPO — World Intellectual Property Indicators 2023
Related questions from earlier years
More from GS Paper 3 2024
Model answer by the EdiShorts editorial team. It is one well-argued treatment of the question, written to the official word limit — not an official UPSC answer key.